Concepedia

Dongliang Li

DL

Statistics

Publications

3

Citations

249

H-Index

3

Active since

2018

Affiliations

Third Affiliated Hospital of Harbin Medical University(Current)

Harbin Medical University

Dongliang Li is an author at Third Affiliated Hospital of Harbin Medical University specializing in molecular oncology, hepatology, and cancer therapeutics.

ORCID

Top concepts

Publications per year

2018–2025

3

Publications

3

Durvalumab with or without bevacizumab with transarterial chemoembolisation in hepatocellular carcinoma (EMERALD-1): a multiregional, randomised, double-blind, placebo-controlled, phase 3 study

Bruno Sangro, Masatoshi Kudo, Joseph P. Erinjeri et al. · The Lancet · 2025 · 151 citations · Full text

, , +8

CADM2, as a new target of miR-10b, promotes tumor metastasis through FAK/AKT pathway in hepatocellular carcinoma

Dongliang Li, Yongjian Zhang, He Zhang et al. · Journal of Experimental & Clinical Cancer Research · 2018 · 79 citations · Full text

SorCS3 promotes the internalization of p75NTR to inhibit GBM progression

Yanqiu Zhang, Yue Li, Yuhua Fan et al. · Cell Death and Disease · 2022 · 19 citations · Full text

1–3 of 3